argenx NV ADR (ARGX)vsPuma Biotechnology Inc (PBYI)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
PBYI
Puma Biotechnology Inc
$6.33
+1.12%
HEALTHCARE · Cap: $317.98M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1755% more annual revenue ($4.24B vs $228.37M). ARGX leads profitability with a 30.5% profit margin vs 13.6%. PBYI appears more attractively valued with a PEG of 0.03. PBYI earns a higher WallStSmart Score of 71/100 (B).
ARGX
Buy63
out of 100
Grade: C+
PBYI
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
-60.0%
Fair Value
$4.15
Current Price
$6.33
$2.18 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Growing faster than its price suggests
Attractively priced relative to earnings
Every $100 of equity generates 28 in profit
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Revenue surging 27.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Smaller company, higher risk/reward
Earnings declined 34.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, P/E Ratio, Return on Equity. Revenue growth of 27.7% demonstrates continued momentum. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, EPS Growth.
Key Dynamics to Monitor
PBYI carries more volatility with a beta of 1.27 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PBYI scores higher overall (71/100 vs 63/100) and 27.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?